Holen Sie sich die Stockscreener-App
4.57
2.56%
-0.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.69
Offen:
$4.65
24-Stunden-Volumen:
1.15M
Relative Volume:
0.61
Marktkapitalisierung:
$431.63M
Einnahmen:
$829.00M
Nettoeinkommen (Verlust:
$-399.90M
KGV:
-1.0589
EPS:
-4.3159
Netto-Cashflow:
$-23.20M
1W Leistung:
+15.11%
1M Leistung:
-9.15%
6M Leistung:
-35.54%
1J Leistung:
-7.11%
1-Tages-Spanne:
$4.53
$4.72
1-Wochen-Bereich:
$3.99
$4.775
52-Wochen-Spanne:
$3.53
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.57 | 442.96M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Director at Myriad Genetics (MYGN) receives 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) director awarded 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) grants 59,701 RSUs to director Mark Davis - Stock Titan
[Form 4] MYRIAD GENETICS INC Insider Trading Activity - Stock Titan
Myriad Genetics (MYGN) director receives 59,701 restricted stock units in equity grant - Stock Titan
Myriad Genetics (NASDAQ: MYGN) director receives 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) grants 59,701 RSUs to board director Bisaro - Stock Titan
Myriad Genetics (NASDAQ: MYGN) director granted 59,701 restricted stock units in equity award - Stock Titan
Myriad Genetics (NASDAQ: MYGN) shareholders approve 2026 equity and purchase plans - Stock Titan
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Myriad Genetics Inc Annual Shareholders Meeting Transcript - GuruFocus
Dr. Crystal Nelson Explains How Genetic Testing Is Transforming Mental Health Medication Treatment on YourUpdateTV - The Manila Times
Myriad Genetics (MYGN) CTO Raj Jampa receives 251,889 restricted stock units - Stock Titan
Myriad Genetics (MYGN) CTO Raj Jampa files initial Form 3 insider report - Stock Titan
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026 - TradingView
Myriad Genetics names Raj Jampa as chief technology officer - Investing.com UK
Myriad Genetics Names Raj Jampa as New Chief Technology Officer - The Globe and Mail
Press Release: Myriad Genetics Names Raj Jampa as New Chief Technology Officer - Moomoo
Statistics Show that Patients Want More Personalized Mental Health Care - KOIN.com
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics, Inc. (MYGN) News, Articles, Events & Latest Updates - Stocktwits
Myriad Genetics Inc stock (US62855J1043): Prolaris AI launch lifts focus - AD HOC NEWS
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - The Globe and Mail
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock - Yahoo Finance
MYGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Myriad Genetics’ Precise MRD Assay Data Presented at ASCO 2026 Shows Potential for Assessing Treatment Response and Monitoring Recurrence in Cancer Patients - geneonline.com
Myriad Genetics Highlights Data Demonstrating Broad Clinical Utility of Precise Mrd Assay At 2026 Asco Annual Meeting - marketscreener.com
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting - The Manila Times
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans - Yahoo Finance
ASCO study: Myriad blood test flags higher cancer recurrence risk - Stock Titan
Myriad Genetics (MYGN) Unveils Innovative Prolaris + AI Test for Prostate Cancer - GuruFocus
Myriad Genetics launches Prolaris + AI prostate cancer test - Investing.com UK
Myriad Genetics launches Prolaris + AI prostate cancer test By Investing.com - Investing.com Nigeria
Myriad Genetics Launches Prolaris® + AI - TradingView
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) - marketscreener.com
Myriad Genetics Launches Prolaris® + AI, the First Prostate - GlobeNewswire
AI-enhanced prostate cancer test to guide active surveillance decisions - Stock Titan
MYGN Technical Analysis & Stock Price Forecast - Intellectia AI
Myriad Genetics (MYGN) price target decreased by 11.49% to 6.35 - MSN
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN) - MSN
Myriad Genetics | 5/22/26 - ktnv.com
MindWalk Holdings Leads Our Trio Of Promising Penny Stocks - simplywall.st
Myriad Genetics executives to speak at SOPHiA GENETICS event, spotlighting industry partnerships - Traders Union
‘American Idol’ Star Speaks Out on Health Issues 17 Years After Show Appearance - Parade
Myriad Genetics in record sell-off after Q1 miss - MSN
Stocks With 20% Upside: Dollar Tree, Myriad Genetics, Antero Resources AnalysisNews and Statistics - IndexBox
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Hold" by Analysts - MarketBeat
Myriad Genetics, Inc. $MYGN Shares Acquired by Vanguard Group Inc. - MarketBeat
Jackie Tohn joins Myriad Genetics in campaign to expand hereditary cancer test awareness - Traders Union
Myriad Genetics, Inc.Common Stock (NQ: MYGN - FinancialContent
Myriad Genetics and actress Jackie Tohn promote hereditary cancer testing after her BRCA1 gene discovery. - Pluang
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Myriad Genetics Inc-Aktie (MYGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Raha Samraat S. | President and CEO |
Mar 09 '26 |
Buy |
5.00 |
40,000 |
199,844 |
493,104 |
| Phanstiel S. Louise | Director |
Feb 26 '26 |
Buy |
4.80 |
50,407 |
242,105 |
233,951 |
| Phanstiel S. Louise | Director |
Feb 27 '26 |
Buy |
4.66 |
48,000 |
223,728 |
281,951 |
| Phanstiel S. Louise | Director |
Feb 25 '26 |
Buy |
4.74 |
6,100 |
28,890 |
183,544 |
2.13%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):